Combination of MLo-1508 with sunitinib for the experimental treatment of papillary renal cell carcinoma.

ABSTRACT: Renal cell carcinoma (RCC) is the 14^th most incident cancer worldwide, and no curative therapeutic options are available for advanced and metastatic disease. Hence, new treatment alternatives are urgently needed to tackle disease management and drug resistance. Herein, we explored the use of MLo-1508 as an anti-tumoral agent in RCC and further assessed its combination with sunitinib for the treatment of papillary RCC. For that, different RCC cell lines were treated with both drugs, alone or in combination, and different phenotypic assays were performed. Moreover, global DNA methylation levels and specific DNMT3a activity were measured, and gene-specific CpG methylation and transcript levels were quantified after treatment. Finally, the combinatory potential of MLo-1508 and sunit

SUBMITTER: Marques-Magalhaes A 

PROVIDER: S-EPMC11973455 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature